ArticleJournal of Cancer2026
Mapping Myeloid Cell Diversity in Diffuse Large B-Cell Lymphoma: Impact on T Cell Exhaustion and Clinical Prognosis.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell lymphoma characterized by genetic variability and clinical heterogeneity. Single-cell sequencing technology enables mapping of intra-tumoral heterogeneity and microenvironment interactions. In this study, we analyzed single-cell and RNA expression microarray data from over 3,000 DLBCL patients to investigate the immune landscape of the tumor microenvironment and its association with clinical prognosis. Malignant B cells identified through B-cell receptor (BCR) clonal analysis and copy number variation (CNV) assessment exhibited enrichment in pathways related to the cell cycle, DNA replication and p53 signaling, which were closely related to adverse survival outcomes. Next, the myeloid cells derived from DLBCL tumor tissues could be further clustered into several distinct types, primarily comprising dendritic cells and macrophages. The increased prevalence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.